QTREX Quantum (QTEX) Current Deferred Revenue (2024 - 2025)
QTREX Quantum's (QTEX) quarterly Current Deferred Revenue came in at $1.6 million in Q4 2025, down 3.84% year-over-year from $1.6 million in Q4 2024, and down 3.84% quarter-over-quarter from $1.6 million in Q4 2024.
Powered by 
Analysis
QTREX Quantum (QTEX) Current Deferred Revenue (2024 - 2025) Analysis & Trends
QTREX Quantum has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $1.6 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 3.84% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (down 3.84% YoY), while the FY2025 annual figure was $1.6 million, down 3.84% from the prior year.
- Current Deferred Revenue came in at $1.6 million for Q4 2025 at QTREX Quantum, down from $1.6 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.6 million in Q4 2024 to a low of $1.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 177.43 Bn | 172.48 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 139.20 Bn | 134.11 Bn | 1.96 Bn |
| 3 | Medtronic | 118.01 Bn | 109.81 Bn | 6.34 Bn |
| 4 | Stryker | 105.44 Bn | 101.96 Bn | 4.50 Bn |
| 5 | Boston Scientific | 62.90 Bn | 62.60 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 50.87 Bn | 46.72 Bn | 1.35 Bn |
| 7 | Dexcom | 33.72 Bn | 31.77 Bn | 830.00 Mn |
| 8 | Resmed | 32.45 Bn | 30.98 Bn | 861.22 Mn |
| 9 | Alcon | 31.70 Bn | 30.25 Bn | 1.68 Bn |
| 10 | QTREX Quantum | 26.07 Mn | 22.91 Mn | - |